Chase Sun Pharmaceutical settles overdue taxes, shareholders approve financial plans

Tianjin Chase Sun Pharmaceutical (SZSE:300026) held its second extraordinary general meeting of shareholders for 2025 on September 16, 2025. Shareholders approved comprehensive credit and guarantee matters for 2025 for the company, its subsidiaries, and sub-subsidiaries, with 98.5812% of votes in favor. The meeting was attended by 725 shareholders representing 23.5379% of total shares.

The company also announced the self-discovery and subsequent payment of overdue taxes and late payment fees. This included 25,166,000 yuan in taxes and 8,672,200 yuan in late payment fees, totaling 33,838,200 yuan. All outstanding amounts have been settled, and no administrative penalties were incurred.

These payments will be recorded as current period expenses in 2025, impacting the company's net profit for the year. The resolution of both the shareholder meeting proposals and the tax obligations signals the company's efforts to manage its financial and regulatory affairs transparently.